Proteostasis Therapeutics Inc. (Nasdaq: PTI) to Ring the Nasdaq Stock Market Opening Bell in Celebration of IPO

ADVISORY, Feb. 11, 2016 --

What: 
Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a company developing novel therapeutics that regulate protein biosynthesis, folding, trafficking and clearance to improve outcomes for patients with protein processing diseases, will visit the Nasdaq MarketSite in Times Square to celebrate its initial public offering (IPO).

In honor of the occasion, Meenu Chhabra, President and Chief Executive Officer, will ring the Opening Bell. 

Where:
Nasdaq MarketSite – 4 Times Square – 43^rd & Broadway – Broadcast Studio

When:
Thursday, February 11, 2016 – 9:15 a.m. to 9:30 a.m. ET

Proteostasis Therapeutics Media Contact:
Dan Budwick
Pure Communications
(973) 271-6085
[email protected]

Nasdaq MarketSite:
Emily Pan
(646) 441-5120
[email protected]

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page:
http://instagram.com/nasdaq

For news tweets, please visit our Twitter page at:
http://twitter.com/nasdaq

For exciting viral content and ceremony photos visit Tumblr Page:
http://nasdaq.tumblr.com/

Webcast:
A webcast of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc. (PTI) is developing disease-modifying therapeutics for diseases of protein processing. Using the DRT™ platform, a phenotypic screening approach based on the use of functionally pertinent cellular assays and disease relevant models, PTI identifies highly selective drug candidates that modulate the proteostasis imbalance in the cell. In addition to its multiple wholly-owned programs in cystic fibrosis, PTI has formed collaborations with Biogen New Ventures Inc. to research and identify therapeutic candidates for neurodegenerative disease and with Astellas Pharma Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway. For more information visit www.proteostasis.com. 

About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.6 trillion and nearly 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-